Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
M Lia Palomba, Brian G Till, Steven I Park, Franck Morschhauser, Guillaume Cartron, Reinhard Marks, Mahesh Shivhare, Wan-Jen Hong, Aparna Raval, Alice C Chang, Elicia Penuel, Leslie L Popplewell, M Lia Palomba, Brian G Till, Steven I Park, Franck Morschhauser, Guillaume Cartron, Reinhard Marks, Mahesh Shivhare, Wan-Jen Hong, Aparna Raval, Alice C Chang, Elicia Penuel, Leslie L Popplewell
Abstract
Background: This was an open-label, phase 1b study assessing the safety, tolerability, preliminary efficacy and pharmacokinetics of the combination of atezolizumab and obinutuzumab in patients with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). There is a mechanistic rationale suggesting that this combination may enhance recruitment of both innate and adaptive immunity and be effective against CD20+ B-cell malignancies.
Materials and methods: The study consisted of a safety evaluation stage and an expansion stage. Patients received obinutuzumab 1000 mg intravenously (IV) in cycle (C) 1, obinutuzumab plus atezolizumab 1200 mg IV for C2-8, and atezolizumab only from C9. Primary endpoints were to identify a recommended phase 2 dose (RP2D) for atezolizumab, and safety and tolerability in the safety and expansion stages.
Results: A total of 49 patients were enrolled (FL, n = 26; DLBCL, n = 23), with a median of 2 prior lines of treatment. The RP2D for atezolizumab was 1200 mg IV every 3 weeks. Adverse events reported in ≥ 20% of patients were fatigue (15 patients [31%]), nausea (13 patients [27%]), cough, and diarrhea (10 patients [20%] each). Objective response rate was 54% in the FL cohort (complete response [CR] rate: 23%) and 17% in the DLBCL cohort (CR: 4%). Median progression-free survival was 9 months for FL and 3 months for DLBCL. Median overall survival was not estimable for FL and 9 months for DLBCL.
Conclusion: The combination of obinutuzumab and atezolizumab was determined to be safe and tolerable, with no new toxicities observed.
Trial registration: ClinicalTrials.gov NCT02220842.
Keywords: Atezolizumab; Diffuse large B-cell lymphoma; Follicular lymphoma; Obinutuzumab.
Copyright © 2021. Published by Elsevier Inc.
Source: PubMed